Table 1.
Baseline Characteristics
| Variable | All Patients (n=1082) | MACE (n=73) | No MACE (n=1007) | P Value |
|---|---|---|---|---|
| Age, y | 63 (53–72) | 72 (61–77) | 63 (52–72) | <0.001 |
| Male sex | 811/1082 (75.0) | 47/73 (64.4) | 763/1007 (75.8) | 0.030 |
| Cardiovascular risk factors | ||||
| Current smoking | 432/1002 (43.1) | 19/66 (28.8) | 412/934 (44.1) | 0.015 |
| Hypertension | 767/1080 (71.0) | 62/73 (84.9) | 703/1005 (70.0) | 0.006 |
| Hyperlipoproteinemia | 410/1074 (38.2) | 25/73 (34.2) | 384/999 (38.4) | 0.477 |
| Diabetes mellitus | 246/1080 (22.8) | 26/73 (35.6) | 219/1005 (21.8) | 0.006 |
| Body mass index, kg/m2 | 27.4 (25.0–30.4) | 27.0 (25.2–31.0) | 27.4 (24.9–30.3) | 0.899 |
| Previous myocardial infarction | 75/1080 (6.9) | 5/73 (6.8) | 69/1005 (6.9) | 0.996 |
| Previous PCI | 90/1081 (8.3) | 5/73 (6.8) | 84/1006 (8.3) | 0.653 |
| Previous CABG | 20/1081 (1.9) | 2/73 (2.7) | 18/1006 (1.8) | 0.561 |
| ST‐segment elevation | 762/1082 (70.4) | 51/73 (69.9) | 711/1007 (70.6) | 0.893 |
| Time from symptom onset to PCI hospital admission, min* | 180 (109–317) | 191 (116–363) | 180 (109–310) | 0.397 |
| Door‐to‐balloon time, min* | 30 (22–42) | 28 (24–40) | 30 (22–42) | 0.497 |
| Killip class on admission | <0.001 | |||
| 1 | 964/1082 (89.1) | 49/73 (67.1) | 913/1007 (90.7) | |
| 2 | 80/1082 (7.4) | 15/73 (20.5) | 65/1007 (6.5) | |
| 3 | 21/1082 (1.9) | 4/73 (5.5) | 17/1007 (1.7) | |
| 4 | 17/1082 (1.6) | 5/73 (6.8) | 12/1007 (1.2) | |
| Number of diseased vessels | 0.012 | |||
| 1 | 541/1082 (50.0) | 26/73 (35.6) | 514/1007 (51.0) | |
| 2 | 327/1082 (30.2) | 24/73 (32.9) | 303/1007 (30.1) | |
| 3 | 214/1082 (19.8) | 23/73 (32.5) | 190/1007 (18.9) | |
| Infarct‐related artery | 0.109 | |||
| Left anterior descending | 443/1082 (40.9) | 39/73 (53.4) | 404/1007 (40.1) | |
| Left circumflex | 218/1082 (20.1) | 13/73 (17.8) | 203/1007 (20.2) | |
| Left main | 6/1082 (0.6) | 1/73 (1.4) | 5/1007 (0.5) | |
| Right coronary artery | 408/1082 (37.7) | 19/73 (26.0) | 389/1007 (38.6) | |
| Bypass graft | 7/1082 (0.6) | 1/73 (1.4) | 6/1007 (0.6) | |
| TIMI flow grade before PCI | 0.617 | |||
| 0 | 550/1082 (50.8) | 42/73 (57.5) | 507/1007 (50.3) | |
| 1 | 121/1082 (11.2) | 5673 (8.2) | 115/1007 (11.4) | |
| 2 | 216/1082 (20.0) | 12/73 (16.4) | 203/1007 (20.2) | |
| 3 | 195/1082 (18.0) | 13/73 (17.8) | 182/1007 (18.1) | |
| TIMI flow grade after PCI | 0.650 | |||
| 0 | 20/1082 (1.8) | 1/73 (1.4) | 19/1007 (1.9) | |
| 1 | 21/1082 (1.9) | 2/73 (2.7) | 19/1007 (1.9) | |
| 2 | 82/1082 (7.6) | 8/73 (11.0) | 74/1007 (7.3) | |
| 3 | 959/1082 (88.6) | 62/73 (84.9) | 895/1007 (88.9) | |
| Concomitant medications | ||||
| Aspirin | 1080/1082 (99.8) | 73/73 (100) | 1005/1007 (99.8) | 0.703 |
| Clopidogrel/prasugrel/ticagrelor | 1082/1082 (100) | 73/73 (100) | 1007/1007 (100) | ··· |
| β‐Blocker | 1032/1080 (95.6) | 71/73 (97.3) | 959/1005 (95.4) | 0.462 |
| ACEI/AT‐1 antagonist | 991/1080 (91.8) | 69/73 (94.5) | 921/1005 (91.6) | 0.386 |
| Aldosterone antagonist | 140/1080 (13.0) | 22/73 (30.1) | 118/1005 (11.7) | <0.001 |
| Statin | 1032/1080 (95.6) | 70/73 (95.9) | 960/1005 (95.5) | 0.883 |
Data presented as n/N (%) or median (interquartile range). P values were calculated for the comparison between patients with and without MACE. AT‐1 antagonist indicates angiotensin II type I receptor antagonist; ACEI, angiotensin‐converting enzyme inhibitor; CABG, coronary artery bypass grafting; MACE, major adverse cardiac events; PCI, percutaneous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction. Two patients were lost to follow‐up regarding MACE.
*
Assessed only in patients with ST‐segment–elevation myocardial infarction (n=795).